A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer

LIU Chunmei; LI Ming; ZHAO Gang

doi:10.7619/jcmp.20201731

Journal of Clinical Medicine in Practice > 2021 > 25(5): 10-15. > DOI: 10.7619/jcmp.20201731

LIU Chunmei, LI Ming, ZHAO Gang. A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 10-15. DOI: 10.7619/jcmp.20201731

Citation:

PDF (4327 KB)

A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer

1.
Department of Oncology, Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing, 400000
2.
Department of Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, 610000

More Information

Received Date: December 19, 2020
Available Online: March 12, 2021
Published Date: March 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To analyze the clinical effect of nitorzumab injection combined with concurrent chemoradiotherapy in the treatment of advanced esophageal cancer.
Methods The databases such as CNKI, Wanfang, VIP, China Biology Medicine (CBM), PubMed, Cochrane Library, Wiley Online Library and Google Academic were searched. The randomized controlled trials (RCT) of nituozumab combined with concurrent chemoradiotherapy (experimental group) and concurrent chemoradiotherapy (control group) were searched. The between-group differences of objective remission rate (ORR), disease control rate (DCR) and drug-related adverse reactions were analyzed by RevMan5.3 software.
Results Totally 9 studies were included, in which 8 studies were Chinese literatures and one study was foreign language literature. Meta-analysis showed that the ORR and DCR of the experimental group significantly improved and the incidence of adverse reactions was not increased.
Conclusion Efficacy and safety of nituozumab injection combined with concurrent chemoradiotherapy are reliable and definite. Rash and change of blood pressure may appear in the course of treatment, but the probability and the degree are relative low.
- esophageal cancer,
- nimotuzumab,
- concurrent chemoradiotherapy,
- systematic analysis

FullText(HTML)

References (21)

References

[1]	HUANG F L, YU S J. Esophageal cancer: Risk factors, genetic association, and treatment[J]. Asian J Surg, 2018, 41(3): 210-215. doi: 10.1016/j.asjsur.2016.10.005
[2]	WATANABE M, OTAKE R, KOZUKI R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer[J]. Surg Today, 2020, 50(1): 12-20. doi: 10.1007/s00595-019-01878-7
[3]	QIU M L, LIN J B, LI X, et al. Current state of esophageal cancer surgery in China: a national database analysis[J]. BMC Cancer, 2019, 19(1): 1064-1073. doi: 10.1186/s12885-019-6191-2
[4]	SINGH D, ATTRI B K, GILL R K, et al. Review on EGFR inhibitors: critical updates[J]. Mini Rev Med Chem, 2016, 16(14): 1134-1166. doi: 10.2174/1389557516666160321114917
[5]	VERA D R, EIGNER S, HENKE K E, et al. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors[J]. Nucl Med Biol, 2012, 39(1): 3-13. doi: 10.1016/j.nucmedbio.2011.07.001
[6]	TSUCHIDA Y, THERASSE P. Response evaluation criteria in solid tumors (RECIST): new guidelines[J]. Med Pediatr Oncol, 2001, 37(1): 1-3. doi: 10.1002/mpo.1154
[7]	BATES D W, O'NEIL A C, PETERSEN L A, et al. Evaluation of screening criteria for adverse events in medical patients[J]. Med Care, 1995, 33(5): 452-462. doi: 10.1097/00005650-199505000-00002
[8]	CUMPSTON M, LI T, PAGE M J, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions[J]. Cochrane Database Syst Rev, 2019, 10: ED000142. http://www.researchgate.net/publication/336750574_Updated_guidance_for_trusted_systematic_reviews_a_new_edition_of_the_Cochrane_Handbook_for_Systematic_Reviews_of_Interventions
[9]	CLARK H D, WELLS G A, HUËT C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale[J]. Control Clin Trials, 1999, 20(5): 448-452. doi: 10.1016/S0197-2456(99)00026-4
[10]	陈玉兰, 李曙平, 练英妮. 尼妥珠单抗联合奈达铂同步放化疗治疗局部晚期食管癌的临床研究[J]. 北方药学, 2016, 13(9): 140-141.
[11]	傅国林. 尼妥珠单抗在局部晚期食管癌同步放化疗中的疗效观察[J]. 中国基层医药, 2017, 24(22): 3457-3461. doi: 10.3760/cma.j.issn.1008-6706.2017.22.025
[12]	侯小霞, 常志伟, 秦艳茹. 尼妥珠单抗联合紫杉醇脂质体、顺铂同步放化疗治疗晚期食管癌的效果[J]. 河南医学研究, 2019, 28(12): 2144-2147. doi: 10.3969/j.issn.1004-437X.2019.12.010
[13]	黄丹丹, 李涛, 张军, 等. 尼妥珠单抗联合同步放化疗治疗局部晚期食管癌的近期疗效分析[J]. 中国肿瘤临床, 2012, 39(23): 1961-1963.
[14]	RAMOS-SUZARTE M, LORENZO-LUACES P, LAZO N G, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy[J]. Cancer Biol Ther, 2012, 13(8): 600-605. doi: 10.4161/cbt.19849
[15]	李明耀, 项振飞, 胡丹飞, 等. 尼妥珠单抗联合同步放化疗治疗局部晚期食管癌效果观察[J]. 中国乡村医药, 2018, 25(24): 15-16. doi: 10.3969/j.issn.1006-5180.2018.24.007
[16]	刘慧娟, 车宇, 刘佳. 尼妥珠单抗联合同步放、化疗治疗中晚期食管癌的近期疗效观察[J]. 现代肿瘤医学, 2015, 23(18): 2587-2590. doi: 10.3969/j.issn.1672-4992.2015.18.10
[17]	周云. 尼妥珠单抗联合洛铂同步放化疗治疗局部晚期食管癌的疗效分析[J]. 临床医药文献电子杂志, 2017, 4(84): 16603-16604. doi: 10.3877/j.issn.2095-8242.2017.84.094
[18]	张云霞, 张健. 尼妥珠单抗联合同步放化疗治疗局部晚期食管癌的短期疗效观察[J]. 心理医生, 2018, 24(25): 173-174.
[19]	FATEHI HASSANABAD A, CHEHADE R, BREADNER D, et al. Esophageal carcinoma: Towards targeted therapies[J]. Cell Oncol (Dordr), 2020, 43(2): 195-209.
[20]	郭晓彤, 赫捷. 食管癌治疗现状及精准医学时代展望[J]. 中华肿瘤杂志, 2016, 38(9): 641-645. doi: 10.3760/cma.j.issn.0253-3766.2016.09.001
[21]	TAYLOR RIPLEY R, SURMAN D R, DIGGS L P, et al. Metabolomic and BH₃ profiling of esophageal cancers: novel assessment methods for precision therapy[J]. BMC Gastroenterol, 2018, 18(1): 94-99. doi: 10.1186/s12876-018-0823-x

[1]	PANG Ting, WU Weili, YANG Binjiao. Pathogen status, risk factors and prediction model construction for catheter-related infection in patients with maintenance hemodialysis[J]. Journal of Clinical Medicine in Practice, 2024, 28(21): 60-65. DOI: 10.7619/jcmp.20243000
[2]	REN Weiwei, WANG Chao, MENG Junhua, XU Suhong. Establishment and validation of an individualized risk prediction nomogram model for gestational diabetes mellitus in pregnant women with hypothyroidism[J]. Journal of Clinical Medicine in Practice, 2024, 28(16): 93-97. DOI: 10.7619/jcmp.20234265
[3]	CHEN Hui, ZHANG Li, LU Chen, CAI Xindi. Establishment and validation of a Nomogram predictionmodel for risk of multi-drug resistant infection after operation of cerebral hemorrhage[J]. Journal of Clinical Medicine in Practice, 2024, 28(8): 45-49, 54. DOI: 10.7619/jcmp.20234252
[4]	WANG Yongxia, CHEN Xiao, LI Mei, JIANG Lijun, DING Hui. Influencing factors of dwarfism in children and construction of the nomogram model[J]. Journal of Clinical Medicine in Practice, 2024, 28(2): 92-95. DOI: 10.7619/jcmp.20232434
[5]	SHI Haomin, YAN Su, QIAO Mengmeng, YANG Huilian. Research on gastric cancer lymph node metastasis prediction model based on machine learning algorithms[J]. Journal of Clinical Medicine in Practice, 2024, 28(1): 41-47, 61. DOI: 10.7619/jcmp.20233076
[6]	DONG Yanping, WANG Jiemin, WANG Yujin, REN Yali, DONG Yucheng, YONG Yanjun, SU Xuandi, WANG Jixiang, SU Nan, WANG Fuli, XIA Duosheng. Construction and evaluation of Nomogram prediction model for postoperative recurrence of pterygium[J]. Journal of Clinical Medicine in Practice, 2022, 26(7): 52-56. DOI: 10.7619/jcmp.20214610
[7]	XU Xiangyanyu, JI Xinyu, SONG Yunjie, XU Xiaoshuang, XU Haiping, ZHANG Ruyang. A study on influence factors of accurate positioning of venous catheter tip in arm infusion port guided by electrocardiogram based on random forest algorithm[J]. Journal of Clinical Medicine in Practice, 2021, 25(19): 7-11. DOI: 10.7619/jcmp.20213117
[8]	ZHANG Xuanyu, SU Zhonghua, BU Ren'ge. Establishment of prognosis related model of localized clear cell renal cell carcinoma[J]. Journal of Clinical Medicine in Practice, 2021, 25(7): 107-110, 114. DOI: 10.7619/jcmp.20201810
[9]	HU Tingting, GUO Qiu, TANG Weiwei, YANG Huan, LIU Guijun. A Nomogram model establishment for noscomial infection in elderly patients with hypertension and diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 55-60. DOI: 10.7619/jcmp.20210055
[10]	ZHANG Zhen, ZHANG Hengzhu, LI Yuping, YAN Zhengcun, DONG Lun, WANG Xiaodong, WANG Xingdong. Relationship between systemic inflammation response index and symptomatic cerebral vasospasm after aneurismal subarachnoid hemorrhage as well as construction of a Nomogram predictive model[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 36-40. DOI: 10.7619/jcmp.202010009

Cited By

Get Citation

PDF

XML

Article views (723) PDF downloads (72)

Turn off MathJax

Article Contents

Abstract

References

A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer

Abstract

References

Related Articles

Catalog

A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content